• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
FDA launches new priority review voucher program for select biopharmas

Maze Therapeutics

Photo of Wall Street street sign with american flags in the background
Biotech

Metsera, Maze go public with IPOs of $275M, $113M

Obesity biotech Metsera and metabolic-focused Maze have met their IPO expectations as the two companies prepare to join the Nasdaq this morning.
James Waldron Jan 31, 2025 7:40am
Business person contemplating how to navigate a maze made of money

Maze rolls out map to $131M IPO

Jan 27, 2025 9:45am
Polaris shining brightly in the night sky

Maze charts path through clinical development with planned IPO

Jan 7, 2025 5:40pm
Business person contemplating how to navigate a maze made of money

Maze finds its way to $115M series D

Dec 3, 2024 12:42pm
Graphic of two hands shaking under a red and purple light

After FTC stalled Sanofi deal, Shionogi bags Maze's Pompe drug

May 10, 2024 5:02am
Graphic image of the words try again on a purple background with some pixelated art below

Sanofi CEO does not rule out future Pompe BD despite FTC moves

Jan 10, 2024 3:37pm

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings